Category: chromosomal instability

  • BMS buys into Volastra’s cancer expertise with $1.1bn alliance

    Bristol-Myers Squibb is the first big pharma to strike a deal with Volastra Therapeutics, a start-up that has developed a drug discovery platform based on chromosomal instability (CIN), a common but under-investigated feature of solid tumours. BMS is paying $30 million into the collaboration upfront, with a total deal value of $1.1 billion, for programmes […]